Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of intravesical EOquin after TUR-BT in noninvasive bladder cancer
2009-015404-26Phase 3Completed
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- Sep 2009
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-muscle-invasive bladder cancer (NMIBC) and bladder cancer comparing EOquin after TUR-BT with Placebo after TUR-BT (2 arms). Primary endpoint: Recurrence rate at 2 years. Started Sep 2009; status: completed.
02
Drugs
apaziquone
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)bladder cancer
Beyond the preview
Go deeper on 2009-015404-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015404-26.